Short Interest in Portage Biotech Inc. (NASDAQ:ALP) Declines By 37.0%

Portage Biotech Inc. (NASDAQ:ALP) was the recipient of a large drop in short interest in the month of July. As of July 31st, there was short interest totaling 944,529 shares, a drop of 37.0% from the July 15th total of 1,498,532 shares. Approximately 4.0% of the shares of the stock are short sold. Based on an average daily trading volume, of 3,047,112 shares, the short-interest ratio is currently 0.3 days.

Wall Street Analyst Weigh In

ALP has been the topic of a number of research analyst reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of Portage Biotech in a research note on Friday, July 24th. HC Wainwright began coverage on Portage Biotech in a report on Monday. They set a “neutral” rating and a $0.25 target price on the stock. One investment analyst has rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Portage Biotech has a consensus rating of “Reduce” and an average target price of $0.25.

Portage Biotech Trading Down 9.7%

Shares of NASDAQ:ALP traded down $0.02 during midday trading on Wednesday, reaching $0.15. The company had a trading volume of 2,901,577 shares, compared to its average volume of 12,258,836. The company has a fifty day simple moving average of $0.28 and a two-hundred day simple moving average of $0.35. The firm has a market cap of $3.45 million, a price-to-earnings ratio of -0.02 and a beta of 0.61. Portage Biotech has a 1-year low of $0.14 and a 1-year high of $13.80. The company has a debt-to-equity ratio of 0.01, a quick ratio of 0.31 and a current ratio of 0.31.

Portage Biotech (NASDAQ:ALP) last announced its earnings results on Thursday, July 16th. The company reported $0.48 EPS for the quarter. The firm had revenue of $0.05 million during the quarter.

Portage Biotech News Summary

Here are the key news stories impacting Portage Biotech this week:

• Positive Sentiment: HC Wainwright initiated coverage of Portage Biotech with a Neutral rating and a $0.25 price target. The target suggests potential upside from recent levels, but the neutral rating indicates limited near-term conviction. HC Wainwright Initiates Coverage on Portage Biotech
• Neutral Sentiment: HC Wainwright expects Portage Biotech to remain unprofitable throughout fiscal 2027, forecasting quarterly EPS of $(0.10) in Q1, $(0.07) in Q2 and Q3, and $(0.06) in Q4. Its full-year FY2027 EPS estimate is $(0.28).
• Positive Sentiment: The firm projects losses will narrow in fiscal 2028, with estimated quarterly EPS of $(0.04) in each quarter and full-year EPS of $(0.17). This implies improving results, though not a return to profitability.
• Negative Sentiment: The persistence of projected losses and Portage Biotech’s limited revenue base provide little evidence of a near-term earnings catalyst. The stock has decreased and is trading near its 12-month low, increasing sensitivity to financing, clinical, and execution risks.
• Neutral Sentiment: A separate article about Alpha Compute Corp. also uses the symbol ALP, but it concerns a different company and is not relevant to Portage Biotech’s valuation or stock performance.

About Portage Biotech

Portage Biotech (NASDAQ:ATON) is a biotechnology company focused on acquiring, developing and advancing therapeutic candidates and platform technologies. The company concentrates its development efforts primarily in areas such as oncology, immunology/inflammation and infectious disease, seeking to move programs from discovery and preclinical stages into clinical development through subsidiary companies and collaborative arrangements.

Portage structures its operations to support a diversified pipeline, advancing both small molecules and biologics by funding preclinical research, conducting clinical trials, and managing regulatory interactions.